Trypanosoma cruzi amastigote adhesion to macrophages is facilitated by the mannose receptor by unknown
Trypanosoma cruzi Amastigote Adhesion to Macrophages Is 
Facilitated by the Mannose Receptor 
By Stuart Kahn,* Monika Wleklinski,* Alejandro Aruffo,~ll 
Andrew Farr,:~w David Coder,w and Maria Kahn* 
From the *Department of Pediatrics, ~.Department of Biologital Structure, and w  of 
Immunology, University of Washington, Seattle, Washington 98195; and [[Bristol-Myers Squibb 
Pharmaceutical Research Institute, Seattle, Washington 98121 
Summary 
Trypanosoma  cruzi is an obligate intracellular protozoan parasite. The mammalian stage  of the 
parasite life cycle describes amastigotes as an intracellular form that replicates, and trypomasti- 
gotes as an extracellular form that disseminates and invades cells. Recent studies, however, have 
demonstrated  that  amastigotes  circulate  in  the  blood  of infected mammals  and  can  invade 
mammalian cells. In this report, a T. cruzi surface glycoprotein gene, SA85-1.1, was expressed 
as  an  immunoglobulin  chimera,  and  this  recombinant globulin  was  used  to  screen  normal 
mouse tissues for adhesive interactions. This approach identified a subset ofmacrophages in the 
skin and peripheral lymph node that bind the T. cruzi surface glycoproteins through the man- 
nose receptor. To further examine the T. cruzi mannose receptor carbohydrate ligands,  the in- 
teraction between T.  cruzi and the mannose-binding protein, a mammalian lectin with similar 
carbohydrate binding specificities as the mannose receptor, was examined. These studies dem- 
onstrated that the mannose-binding protein recognized amastigotes, but not trypomastigotes or 
epimastigotes, and suggested that amastigotes would also be recognized by the rnannose recep- 
tor. Therefore, amastigote adhesion to macrophages was investigated, and these experiments 
demonstrated that the mannose receptor contributes to amastigote adhesion. The data identify 
the first mammalian lectins that bind to T. cruzi,  and are involved in T. cruzi invasion of mam- 
malian cells. The data suggest that amastigotes and trypomastigotes may have developed differ- 
ent mechanisms to adhere to and invade host cells.  In addition,  it has  been established that 
IFN-',/-activated macrophages express low levels of the mannose receptor and are trypanocidal; 
this  suggests  that  the  interaction  between  amastigotes  and  the  mannose  receptor  enables 
amastigotes to increase their adherence with a population ofmacrophages that are nontrypano- 
cidal and permissive for their intracellular replication. 
rypanosoma  cruzi,  which  causes  Chagas  Disease  or 
merican Trypanosomiasis, is an obligate intraceUular 
protozoan parasite of mammals. Infection frequently begins 
when reduviid bugs deposit metacyclic trypomastigotes on 
the skin. The parasites penetrate the skin through abrasions, 
and disseminate in the lymphatics and circulation (1). Try- 
pomastigotes may transform into amastigotes in the extra- 
cellular  milieu  (2),  and  recent  experiments  indicate  that 
both  arnastigotes  and  trypomastigotes invade  mammalian 
cells  (3). After the initial invasion of the cells, parasites  are 
found within lysosomes, from which they escape to repli- 
cate  in  the  cytoplasm  (4).  Following  replication,  some 
amastigotes  transform into  trypomastigotes.  Both  amasti- 
gotes and trypomastigotes are released from dying cells to 
potentially invade other cells.  During the infection, para- 
sites  are found proliferating within macrophages; IFN-',/- 
activated macrophages, however, are trypanocidal (5). 
The  macrophage  mannose  receptor  (MR) 1,  a  C-type 
lectin, is a membrane glycoprotein that is constitutively re- 
cycled between the plasma  membrane and the endosomal 
compartment (6). The binding ofligands to the MR is cal- 
cium dependent, and sensitive to pH; this pH sensitivity fa- 
cilitates  the  release of ligands in  the  endosomal compart- 
ment (6).  The MR preferentially binds to glycoconjugates 
terminating  in  mannose,  fucose,  or  N-acetylglucosamine 
(6). Few host glycoconjugates have these terminal carbohy- 
drates,  whereas  many microorganism glycoconjugates do, 
which enables the MR to bind microorganisms and inter- 
1Abbreviations used in this  paper: LIT, liver  infusion/tryptone  media; MBP, 
mannose-binding proteins; m.o.i., multiplicity of infection; MR, man- 
nose receptor; Rg, recombinant  globulin; P,  PMI-BH, RPMI with 0.2% 
BSA and 10 m/Vl Hepes; TBS, tiffs-buffered  saline with 2 mM CaCI  2 and 
2 mM MgC12. 
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phages (6). 
Mannose-binding proteins (MBP) are C-type lectins that 
circulate in  the  blood  of mammals.  MBPs  have  a  similar 
carbohydrate binding specificity as the MR,  as MBPs  also 
bind to glycoconjugates terminating in mannose, fucose, or 
N-acetylglucosamine (7). The MBPs may be considered as 
"ante"  antibodies;  they  distinguish between  the  oligosac- 
charides that decorate a variety of pathogenic microorgan- 
isms (including yeasts, bacteria, and viruses)  from self gly- 
coproteins (8). The analogy of MBP to antibodies extends 
to the ability of MBP to directly opsonize microorganisms 
or to initiate activation of the complement cascade (9). 
Studies have indicated that the  T.  cruzi surface glycopro- 
teins  facilitate adhesion  and  invasion  of mammalian  cells 
(10-18).  Many  of the  parasite  surface  glycoproteins  are 
members ofa superfamily defined by homology to sialidase 
(19-27).  A  minority of these glycoproteins function as the 
parasite sialidase/trans-sialidase  (19,  24,  26,  27).  We  have 
previously  defined  the  SA85-1  (surface  antigen,  85  kD) 
glycoprotein family  that  is  both  a  subset  of the  sialidase 
superfamily, and a  subset of the major amastigote and try- 
pomastigote  surface  glycoproteins  of ~85  kD  (23,  28). 
Biochemical analysis has indicated that the  SA85-1  glyco- 
proteins  lack  sialidase/trans-sialidase  activity,  raising  the 
possibility that  they  function  as  the  previously  described 
adhesion molecules, capable of binding to the mammalian 
cell surface (29). To investigate this possibility, we have ex- 
pressed two SA85-1 genes, SA85-1.1 and SA85-1.2, as im- 
munoglobulin chimeras to  identify tissues and  cells of tis- 
sues that may bind these  T.  cruzi surface glycoproteins. We 
report  here  that  this  approach  has  defined  an  interaction 
between  amastigotes  and  both  the  macrophage  MR  and 
the MBP.  The interaction with the MR  facilitates the ad- 
hesion of amastigotes to macrophages. IFN-y down-regu- 
lates MR  expression; this suggests that the interaction be- 
tween amastigotes and the MR  will favor parasite invasion 
and  replication in  macrophages  that  have  not  been  acti- 
vated by IFN-% 
Materials and Methods 
T.  cruzi.  T.  cruzi  CL  strain subclone three  was  used  (30). 
Amastigotes and trypomastigotes were obtained from culture su- 
pernatants of infected rat 3T3  cells grown in DME  (Bio Whit- 
taker Inc., Walkersville, MD) with 10% calf  serum (Hyclone Lab- 
oratories Inc., Logan, UT). In these supernatants, the amastigote/ 
trypomastigote ratio varied from 5:1 to 1:1. 
Axenically derived amastigotes were  obtained by incubating 
amastigotes and trypomastigotes isolated from 3T3 culture super- 
natants in liver infusion/tryptone medium (LIT) at 37~  for 24 h 
(3).  These axenically derived amastigotes were pelleted by cen- 
trifugation at 1,000 g for 5 min (3). Before use in subsequent ex- 
periments, all parasites were washed three times in media without 
supplemental serum. LIT media was prepared by mixing 0.025  g/1 
hemin (bovine, type I; Sigma Chemical Co., St. Louis, MO) dis- 
solved in 5 ml of 0.01  M  NaOH with a 900 ml solution contain- 
ing 4.0 g NaC1,  0.4 g KCI, 8.0 g Na2HPO4, 2.0 g glucose, 5.0 g 
Liver Infusion (Difco Laboratories Inc., Detroit, MI), and 5.{) g 
tryptose (Difco Laboratories Inc.). These amastigotes were con- 
taminated with < 1% trypomastigotes. 
Mice and Rabbits.  Female BALB/c mice were purchased from 
Bantin and Kingman,  Inc.  (Fremont, CA).  New Zealand White 
rabbits were purchased from R  and R  Rabbitry (Stanwood, WA). 
Reagents.  mAbs F4/80 (the gift of C. B. Wilson, University 
of Washington, Seattle, WA) and N418 were used in the form of 
culture medium from exhaustively grown hybridomas (31,  32); 
whereas,  mAbs M1/70  and M3/84  were purified from  culture 
supernatants (33, 34). mAb MOMA-2 supernatant was purchased 
from  Harlan  Bioproducts  for  Science,  Inc.  (Indianapolis,  IN) 
(35). SER-4 mAb was the gift of Dr. P. Crocker (John Radcliffe 
Hospital, Oxford, UK)  (36).  The anti-mouse MR antibody was 
the gift of Dr. P. Stahl (Washington University, St. Louis). The 
anti-human MBP mAb was the gift of Dr. R.  A. B. Ezekowitz 
(Harvard  University,  Boston)  (37).  Human  IgG  mAb  (Sigma 
Chemical  Co.)  and  rat  IgG  mAb  (Zymed  Laboratories,  Inc., 
South San Francisco, CA)  secreted by myeloma cell lines were 
used  as  immunohistochemical  controls.  MOPC-21  mAb,  se- 
creted by a murine myeloma cell line was a gift from D. Lewis 
(University of Washington, Seattle, WA). 
Anti-SA85-1.1  antibodies were  produced  by  immunization 
with SA85-1.1 protein expressed in E.  coli and isolated from in- 
clusion bodies as described (23).  A rabbit was repeatedly immu- 
nized with 100  Izg of this SA85-1.1 protein, and anti-SA85-1.1 
antibodies were affinity purified from rabbit serum with a SA85- 
1.1  affinity column  as described (23).  These  anti-SA85-1  anti- 
bodies  specifically recognize  SA85-1  recombinant  proteins  in 
ELISA and Western blots  (not  shown).  To  generate  the  anti- 
SA85-1 mAb, a mouse was immunized with the same SA85-1.1 
protein. Standard procedures were followed to produce hybrido- 
mas and to isolate the resulting mAb (38). The anti-SA85-1 mAb 
recognized both trypomastigotes and amastigotes in flow cytome- 
try,  and  recombinant  SA85-1  proteins in  ELISA (not  shown). 
The anti-SA85-1 mAb and the polyclonal anti-SA85-1 antibod- 
ies both appear to detect a similar broad band in Western analysis 
of T.  cruzi  mammalian stage lysates  following one-dimensional 
SDS-PAGE (not shown). 
FITC-conjugated goat anti-human antibodies were purchased 
from Tago hnmunologicals (Burlingame, CA) and Jackson Im- 
munologics (West Grove, PA). FITC-conjugated goat anti-rabbit 
and anti-rat antibodies were purchased from Tago. Biotin-conju- 
gated goat anti-rat and anti-hamster were purchased from Caltag 
Labs (South San Francisco, CA). Texas Red-conjugated strepavi- 
din was purchased from Molecular Probes (Eugene, OR). 
To create SA85-1-immunoglobulin fusion proteins, PeR was 
used to amplify the SA85-1.1 and SA85-1.2 DNA from plasmids 
as previously described (23);  synthetic oligonucleotides designed 
to  allow fusion  to  the  human  IgG1  artificial spliced donor se- 
quences were used  (39).  To  amplify the DNA, 30  cycles were 
conducted, consisting of 30 s at 94~  2 min at 45~  and 3 min 
at 72~  using the buffer recommended by the enzyme vendors 
(Cetus,  Emeryville, CA).  To  construct  SA85-1.1  recombinant 
globulin (Rg), the forward primer was GCGAAGCTTCCGC- 
CGAGGCCCAACATG, and the reverse primer was  GCGCA- 
GATCTCTCCCGTACGCGGAAAC;  the  sequence  allowed 
the SA85-1.1 fragment to be inserted as a HindllI to BgllI frag- 
ment into HindlII- and BamHI-digested IgG expression vector. 
To facilitate the secretion of the SA85-1.2 immunoglobulin fu- 
sion protein, the SA85-1.2 DNA fragment was fused to the CD5 
secretory signal sequence in the immunoglobulin expression vec- 
tor. To construct SA85-1.2 Rg, the forward primer was GCGC- 
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primer was CGCGAGATCTCTCCCGTACGCGGAACCAGC; 
the sequence allowed the SA85-1.2 fragment to be inserted as a 
KpnI to BgllI fragment into KpnI- and BamHI-digested vector. 
The  SA85-1  iLg  expression  plasmids  were  transfected  into 
COS cells using DEAE dextran as previously described (40). 24 h 
after transfection,  cells were trypsinized,  seeded  onto fresh  100- 
mm dishes, and allowed to grow for 7 d in 10 ml of DME. On 
the fourth day 10 additional ml of DME was added. Supernatants 
were  harvested,  centrifuged  to  remove  cells and  debris,  and 
passed  over a protein A  column (R.epligen,  Cambridge, MA). 
The  SA85-1  Rgs  were  eluted  from  the  column with  citrate 
buffer, pH 3.0, dialyzed into PBS, and stored at 4~ 
Radiolabeled SA85-1  Rgs were produced by the addition of 
0.25  mCi of [35S]methionine and  [35S]cysteine (NEN,  Boston, 
MA) in DME lacking methionine, to COS cell cultures 24 h after 
transfection with expression plasmids. After overnight incubation 
the supernatants  were harvested,  cells and debris were removed 
by centrifugation, incubated with protein A-Sepharose (Pharma- 
cia LKB Biotechnology Inc., Piscataway, NJ), washed, and eluted 
with SDS-PAGE sample load buffer with and without DTT. 
The SA85-1.1  Rg with a mutated Fc domain to prevent bind- 
ing to  Fc receptors  was constructed by digesting SA85-1.1  Rg 
with MluI and Bglll, and inserting the SA85-1.1  DNA fragment 
into the expression vector with the mutated Fc domain (41, 42). 
Recombinant human MBP  (the  gift of R.  A. B.  Ezekowitz, 
Harvard University, Boston) was purified by mannan chromatog- 
raphy from tissue culture supernatants  of mouse myeloma cells 
that express a transfected human MBP gene (43). 
Carbohydrates  were purchased  from Sigma Chemical Co. 
12-ram  round  coverslips  (Fisher  Scientific,  Pittsburgh,  PA) 
were washed by incubation in Chromerge (Manostat Corp., New 
York, NY), followed by rinsing with water,  and storage in 95% 
ethanol (44). 
Acid-washed  coverslips,  to  be  derivatized  with  mannan or 
BSA, were placed in 24-well plastic  tissue culture plate (Corn- 
ing Glass Works, Coming, NY) and 0.3 ml of 0.1 mg/ml poly- 
L-lysine was  added.  After 30-min incubation at  room temper- 
ature, the coverslips were washed and incubated with 2.5% glut- 
araldehyde  for 15 rain at room temperature. The coverslips were 
then washed,  aspirated dry, and 0.3 ml of PBS containing either 
50 mg/ml BSA or mannan with 10 mg/ml 1-ethyl-3-(di-methyl- 
amino-propyl) carbodiimide was  added to  the  coverslips.  After 
60  min at  room temperature,  the  coverslips  were  washed  and 
incubated in PBS with 1.5 g/100 ml glycine and 1 mg/ml BSA 
at  4~  overnight. Before  use  the  coverslips were  washed  with 
PBS (44). 
Immunohistochemical Procedures.  The techniques used for light 
immunohistochemistry have been described  in detail  (45). For 
light microscopic immunohistochemical analyses, frozen sections 
of tissue were mounted on amino alkylsilane-treated  slides and al- 
lowed to air dry for at least 30 min before fixation (20 rain in ac- 
etone at -20~  (46). After rinsing in Tris-buffered saline with 2 
mM CaC12 and 2 mM MgC12 (TBS), the sections were incubated 
for 1 h at room temperature with antibodies or recombinant pro- 
teins (20 I~g/ml or 2 I~g/slide). Antibodies and SA85-1 recombi- 
nant proteins were diluted into TBS with 10% normal mouse se- 
rum and 10% normal goat  serum.  After several washes in TBS, 
slides were incubated with fluorochrome-conjugated antibodies, 
or rabbit anti-SA85-1.1 antibodies for  1 h at room temperature. 
If necessary slides were washed  again with TBS, and incubated 
with Texas red-conjugated strepavidin or FITC-conjugated  anti- 
rabbit antibodies.  Slides were  washed  a  final  time  with  TBS, 
mounted with coverslips,  and photographed using a Microphot 
FXA (Nikon, Tokyo, Japan). 
In experiments investigating the  effect  of cation concentra- 
tions,  slides with  LNs  were  fixed  with  acetone,  washed  with 
TBS, and incubated at room temperature for 1 h with TBS con- 
taining 10% mouse serum, 10% goat serum, and 10% BSA. Slides 
were then washed with TBS containing the appropriate  concen- 
tration of cation, and then incubated with SA85-1.1  1Lg diluted 
in TBS containing the appropriate  concentration of cation. The 
remainder of the staining was performed as described above. Sim- 
ilarly, to determine the effects ofpH on the binding of SA85-1.1 
Rg,  slides were  initially incubated with  TBS  containing 10% 
mouse serum,  10% goat serum, and 10% BSA. Slides were then 
washed  in glycine-buffered saline  of the  appropriate  pH,  and 
SA85-1.1 Rg was diluted in the glycine-buffered  saline of the ap- 
propriate pH. 
Biochemical Procedures.  Lysates of mammalian stage parasites 
were prepared by removing culture media from infected rat 3T3 
cells; debris was removed with a centrifugation at 50 g for 5 rain. 
Parasites were then pelleted by centrifugation at 2,000 g for 15 
rain, and washed three times in serum-free media. The final pellet 
was then resuspended  at 2 ￿  108 amastigotes and 2 ￿  10  s trypo- 
mastigotes/ml in 10 mM tris, pH 8.0, 1% NP-40, PMSF 100 t~g/ 
ml, pepstatin  1 txg/ml, and leupeptin 1 Ixg/ml.  The suspension 
was incubated on ice for 10 rain, and then centrifuged at 16,000g 
for 10 rain at 4~ 
PNGase F treatment was performed by mixing 10 Ixl oflysate 
with 2 I~1 10￿  denaturation buffer (New England Biolabs, Bev- 
erly, MA), and 8 I.U of water,  and heated at  100~  for 10 min. 
The reaction was cooled on ice,  and then 3 p2 of 10￿  reaction 
buffer (New England Biolabs), 3 I~1 of 10% NP-40, and 4 Ixl of 
PNGase F (4000 U; New England Biolabs) was added. The reac- 
tion was then incubated at 37~  for 16 h. Half of the reaction was 
subjected to SDS-PAGE and Western analysis. The mock sample 
was prepared in the same manner in parallel, except that PBS was 
substituted for the 4 Ixl ofPNGase F. 
SDS-PAGE  was  performed  following  standard  procedures 
(47). Pore exclusion limit electrophoresis  gels were 4--15% acryl- 
amide  (3-12%  glycerol)  gradient in  0.5￿  tris-buffered  EDTA 
(48). Electrophoresis  was continued for 18 h at 4~  (20 V/cm) 
(48).  Thyroglobulin (669  kD),  ferritin (440  kD),  catalase (232 
kD), aldolase (158 kD), and bovine serum albumin (67 kD) were 
used as molecular size standards (Pharmacia). 
Western analysis followed protocols  for semidry transfer  (49). 
Bound antibodies were detected using a rabbit anti-mouse IgG 
antibody conjugated to horseradish peroxidase  (Zymed Laborato- 
ries, Inc.), followed by enhanced chemiluminescence (Amersham 
Corp., Arlington Heights,  IL) and exposure to x-ray film, or with 
an anti-mouse IgG antibody conjugated to alkaline phosphatase 
(Promega  Corp., Madison, WI), and reacted  with bromochlor- 
oindolyl phosphate/nitro blue tetrazolium  (Bio-Rad Labs., Rich- 
mond, CA) (49). The anti-SA85-1 mAb was used at 10 txg/ml. 
The anti-SA85-1 antibodies were used at 10 ~g/ml. 
Gels for autoradiograms  were incubated with Enhance (NEN) 
according to the manufacturers  instructions. 
Flow  Cytometry.  Parasites  were  incubated with  human re- 
combinant MBP or control proteins in HBSS.  Unless indicated 
HBSS  was  made with 2  mM CaC12 and without Glucose and 
magnesium salts. Following incubation for 30  rain at  0~  the 
parasites  were  washed  three  times  in  HBSS,  fixed  with  4% 
paraformaldehyde  (J.  T.  Baker  Inc.,  Phillipsburg,  NJ)  in PBS, 
washed  three more times in PBS,  and then incubated with an 
anti-human MBP mAb for 30 rain at 0~  (37). The bound mAb 
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FITC  (Tago  Inc.,  Burlingame,  CA).  The  fixed  parasites  were 
then subjected to flow cytometry on a FACScan (Becton Dickin- 
son, San Jose, CA). A minimum of 10,000 events were collected 
and the data was analyzed with ILeproMan (TrueFacts Inc., Seat- 
tle, WA). 
Macrophages.  J774E macrophages were the gift of Dr. P. Stahl 
(50). J774A.1  macrophage were the gift of Dr. W. Van Voorhis 
(University of Washington,  Seattle).  Both J774  cell lines were 
grown in DMEM  or-media (GIBCO BILL,  Gaithersburg, MD) 
supplemented with  10% FCS (Hyclone). The macrophages were 
grown on 12-ram coverslips for adhesion assays. 
Human  macrophages  were  derived  from  peripheral  blood 
monocytes. 15 ml of blood from human volunteers, mixed with 
0.3 ml of 10% K2EDTA, was combined with an equal volume of 
normal saline, and was  then underlaid with  10 rnl Ficoll-Paque 
(Pharmacia)  and centrifuged at  500 g  at  t8~  for  20  min. The 
PBMC  at the  interface were  removed,  mixed with HBSS,  and 
centrifuged at  1200 rpm at  18~  for  10 min. The PBMC were 
washed with HBSS  and centrifuged as above three more  times. 
The  PBMC  were  resuspended  in  serum-free  media  (GIBCO 
BILL) at 2.5 ￿  106 cells/ml, and 10 ml of this cell suspension was 
placed in Teflon beakers (Savillex Corp., Minnetonka, MN), and 
cultured at 37~  in a 5% CO2 incubator for 3-7 d. 5 ml of media 
was replaced on alternate days. On the day of each experiment, 
loosely adherent PBMC  were discarded by swirling the beakers 
and pouring offthe media. Then 5 ml of ice-cold ILPMI contain- 
ing 0.2% BSA and 10 mM Hepes  (ILPMI-BH) was added to the 
beakers,  incubated on ice for 30 min, and the adherent PBMC 
were loosened by repeated pipetting with a control drop pasteur 
pipette. The cells were collected and washed twice with RPMI- 
BH.  The PBMC  were  resuspended at  1  ￿  10S/ml and  100  p~l 
were layered onto the surface ofa 12-mm acid-washed coverslip. 
After 1 h the coverslips were washed with RPMI-BH six times to 
remove loosely adherent PBMC (44). 
Thioglycollate-elicited mouse  peritoneal  macrophages  were 
isolated by injecting Balb/c mice with 1 ml of Brewer's Thiogly- 
collate (Difco Laboratories, Inc.) in the peritoneum. 3 d later the 
peritoneum was  lavaged with  5  ml PBS  to  obtain the  macro- 
phages.  The macrophages were then washed three times, resus- 
pended in ILPMI containing 10% FCS at 1  ￿  10  s macrophages/ 
ml, and 100 ~1 of cell suspension was plated onto 12-mm acid- 
washed  coverslips and cultured at 37~  for  1  h.  The  coverslips 
were then washed three times to remove loosely adherent cells. 
Adhesion Assays.  Macrophages adherent on 12-mm glass cov- 
erslips  were  placed  in  individual wells  containing ILPMI  only. 
Amastigotes were added in ILPMI in the absence or presence of 
inhibitors of the MIL (mannan or mannose-BSA; Sigma Chemi- 
cal  Co.)  or controls  (glucan or galactose-BSA; Sigma Chemical 
Co.). To permit the addition of pure populations ofamastigotes, 
axenically derived amastigotes were used, which were isolated as 
described above  (3).  After  1-2  h  at  37~  the  free  amastigotes 
were removed by washing and the cells were fixed, made perme- 
able,  and  stained  with  4',6-diamidino-2-phenylindole (Sigma 
Chemical  Co.).  In  the  fluorescent microscope  (Microphot  Fx, 
Nikon)  200  macrophages  were  scored  for  association  with 
amastigotes. Amastigotes were detected by the characteristic fluo- 
rescent staining pattern of the kinetoplast. Phase microscopy was 
used to confirm that the amastigotes were in contact with a mac- 
rophage.  This  assay  did  not  attempt  to  differentiate  between 
amastigotes that  have adhered  to  the macrophage surface or in- 
vaded the macrophage.  An investigator not informed of sample 
treatment counted each  sample in triplicate.  Macrophages  were 
scored for being associated with amastigotes, and for being associ- 
ated with greater than one amastigote. 
Statistical Methods.  Data are expressed as mean +  standard er- 
ror of the mean. Differences between experimental groups were 
assessed by a paired two-sample Student's t test. Statistical testing 
was accomplished with the Microsoft Excel 5.0 statistical  package 
(Microsoft Corporation, Redmond, WA). 
Results 
SA85-1  Smface  Proteins  are  Glycosylated  and  Expressed  as 
Dimers.  To begin to  characterize the glycosylation of the 
SA85-1 glycoproteins, mammalian-stage parasite lysates were 
subjected  to  PNGase  F  (peptide:  N-glycosidase  F)  treat- 
ment  or  mock  treatment,  followed  by  SDS-PAGE  and 
Western analysis with an anti-SA85-1 mAb (Fig.  t  a). The 
data  indicated  that  the  glycosidase  removed  20  kD  of 
N-linked oligosaccharides from the SA85-1  glycoproteins. 
To  further  examine the  structure  of the  SA85-I  glyco- 
proteins,  mammalian stage lysates and culture supernatants 
containing  spontaneously  shed  mammalian  stage  surface 
glycoproteins were subjected to native PAGE (pore exclu- 
sion  limit  analysis)  and  SDS-PAGE  followed  by Western 
analysis. Native PAGE demonstrated  that the  SA85-1  gly- 
coproteins were expressed and shed as 200-kD dimers (Fig. 
1  b);  SDS-PAGE  revealed  that  the  SA85-1  glycoproteins 
migrated at  100 kD  using nonreducing and reducing con- 
ditions  (Fig.  1  c).  Together  the  data  suggested  that  the 
SA85-I  glycoproteins are synthesized and secreted  as non- 
covalent dimers. 
Preparation  of  Soluble  SA85-1  Immunoglobulin  Fusion 
Proteins.  To  investigate  the  interactions  of the  SA85-1 
glycoproteins  with  mammalian tissue,  two  SA85-1  genes 
Figure 1.  Structural analysis of SA85-1 proteins. (a) The SA85-1 pro- 
teins are glycosylated. Mammalian-stage lysates  were subjected to PNGase 
F treatment  or mock  treatment,  followed by SDS-PAGE and Western 
analysis using an anti-SA85-1 mAb. (b) The SA85-1 glycoproteins are ex- 
pressed and secreted as dimers. 3 #xg of spontaneously shed (S) or mam- 
malian-stage lysate (L) were electrophoresed on a 4-15% nondenaturing 
polyacrylainide gel until the limit of migration was reached, followed by 
Western analysis using an anti-SA85-1  nLAb. (c) The SA85-1 glycopro- 
tein dimers are not dependent on sulfhydryl-bonds. 3 l,  Lg of spontaneously 
shed  (S)  or mammalian-stage lysate (L)  were  subjected to  SDS-PAGE 
(7.5% gel) using nonreducing (-2-ME)  or reducing (+2-ME)  condi- 
tions, followed by Western analysis  using an anti-SA85-1 antibody. 
1246  7". cruzi Amastigotes Bind the Macrophage Mannose Receptor Figure  2.  Schematic  diagram,  structure,  and  purification  of SA85-I 
lags.  (a) Structure of SA85-1.1  lag and SA85-1.2 lag genes. The SA85-1 
domains are represented by boxes. S, secretory signal sequence; SH, siali- 
dase homology domain; and C, carboxyl-terminal domain. Antibody ex- 
ons (human IgG1) are stippled, and introns are connected by solid lines. 
H,  CH2,  and CH3  denote  the IgG hinge,  CH2,  and CH3  constant re- 
gion exons, respectively. (b) SA85-1.1  lag and SA85-1.2 lag form dimers. 
SA85-1.1  lag and SA85-1.2  lag radiolabeled with  [3SS]methionine were 
subjected  to  SDS-PAGE  (6%  gel);  lane  I  (SA85-1.1  lag)  and  lane  2 
(SA85-1.2 lag) reducing conditions; and lane 3 (SA85-1.1 lag) and lane 4 
(SA85-1.2 lag) nonreducing conditions.  (c) Commassie blue stained pro- 
tein A  column purified SA85-1.1  lag (lane  1) and SA85-1.2 lag (lane 2) 
following SDS-PAGE  (7.5% gel); samples were exposed to reducing con- 
ditions. 
were  expressed  as  immunoglobulin fusion  glycoproteins 
using  COS  cells.  These  immunoglobulin chimeras  were 
produced  by  genetic  fusion  of the  SA85-1.1  (genomic 
DNA and cDNA hybrid segment) and SA85-1.2 (genomic 
DNA  segment)  to  the  genomic DNA  segment encoding 
human IgG1  (Fig. 2 a)  (23). Expression plasmids  encoding 
these constructs directed the production of soluble SA85-1 
Rg dimers into  the supernatant of transfected COS  cells 
(Fig. 2  b).  The SA85-1  P,  gs were purified from the COS 
cell supematants with protein A (Fig. 2 c). 
Soluble SA85-1.1  Recombinant  Proteins React with Skin and 
LN  Macrophages.  Immunohistochemistry  was  used  to 
identify mammalian tissues and cells which react with SA85-1 
Rgs. SA85-1.1  Rg binding was detected to scattered cells 
in the skin dermis (Fig 3 a). No staining ofSA85-1.2 Rg to 
the skin thin section was observed (Fig. 3 b); similarly an ir- 
relevant human IgG1 antibody did not stain the skin (Fig. 3 
c).  In  the  peripheral  LN,  SA85-1.1  Rg was  observed  to 
stain subcapsular  sinuses  and T  cell-dependent areas,  and 
not to stain B cell follicles  (Fig. 4, a-d). Often, the SA85- 
1.1 Rg  + cells appeared as groups of cells that involved and 
surrounded the peripheral LN lymphatics that link the cap- 
sule  to  the  medulla  (interfollicular sinuses)  (Fig.  4,  a-d). 
Again, no staining by SA85-1.2 Rg (Fig. 4 e), or an irrele- 
vant human IgG1  antibody (Fig.  4J)  was observed.  The 
staining of SA85-1.1  l<g to subcapsular  and interfollicular 
sinuses suggested an interaction with macrophages, a prom- 
inent cell type of these locations. 
To define the cell lineage of the binding cells (SA85-1.1 
R.g  §  cells),  two  color immunofluorescence with cell lin- 
eage-specific mAbs and SA85-1.1  R.g was performed (not 
shown).  In  skin,  SA85-1.1  R.g staining colocalized with 
some dermal  macrophages identified by mAb  F4/80  and 
M1/70 (not shown) (31, 51, 52). There was no colocaliza- 
tion with epidermal Langerhans cells detected by mAb F4/ 
80 (not shown) (51). 
In  peripheral  LN  all  SA85-1.1  Rg  +  cells  were  also 
stained by the macrophage specific mAbs M1/70, M3/84, 
and MOMA-2  (not shown)  (35,  52,  53).  Some SA85-1.1 
R.g  + cells colocalized with F4/80 + macrophages, and some 
did not (not shown) (31,  51, 52).  There was also colocal- 
ization of SA85-1.1  R.g  + cells and the SER.-4 mAb which 
detects a subset of macrophage in the LN (not shown) (36, 
54).  There was no detectable colocalization with the den- 
dritic cell specific mAb N418 (not shown) (32). 
Labeling macrophages  with  SA85-1.1  Rg was  not the 
result of Fc interactions. These immunohistochemical stud- 
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Figure  3.  Reactivity  of SA85- 
1.1  lag with cells of the skin.  (a) 
SA85-1.1  lag staining of dermal 
cells.  Arrows  indicate  scattered 
labeled cells,  and arrowheads in- 
dicate  autofluorescence  of  hair 
shafts.  (b)  Staining  with  SA85- 
1.2 Rg, and (c) with an irrelevant 
human IgG1 antibody. Only au- 
tofluorescence  of hair shafts  and 
connective  tissue  is  visible. 
￿ Figure 4.  Reactivity  ofSA85-1.1 Rg with peripheral LN. (a--d) SA85-1.1 Rg localizes to subcapsular and interfollicular regions, sparing follicles. (FO) 
Follicles. (Arrowheads)  Subcapsular sinuses. (*) Interfollicular  sinuses. Staining with SA85-1.2 Rg (e) and an irrelevant human IgG1 antibody ~r ). ￿ 
except b ￿ 
ies were performed in the presence of 10%  normal mouse 
serum to prevent detectable FcR interactions.  Using these 
conditions,  neither SA85-1.2  Rg nor an irrelevant human 
IgG1  bound  to  the  tissues  indicating  that  nonspecific hu- 
man Fc interactions were not occurring (Figs.  3 and 4).  In 
addition,  the  SA85-1.1  gene was expressed fused to a hu- 
man IgG1 Fc that has been genetically modified to prevent 
the  binding  to  Fc  receptors  (called SA85-1.1  Rg-m)  (41, 
42).  The binding of SA85-1.1  Rg-m and SA85-1.1  Rg to 
peripheral LN serial thin sections was indistinguishable (not 
shown). 
Carbohydrates Block the Binding of Soluble SA85-1  Glyco- 
proteins.  Previous studies indicated that mannose, galactose, 
N-acetyl-D-glucosamine and mannan inhibit  the  adhesion 
and  invasion  of T.  cruzi into  mammalian cells,  suggesting 
that carbohydrates were critical to infection (55-58). There- 
fore, the binding of SA85-1.1  Rg to LN macrophages was 
examined in  the presence of these sugars  and others.  Spe- 
cific  carbohydrates  (mannose,  fucose,  N-acetyl-D-glucos- 
amine,  and  mannan)  were  shown  to  inhibit  the  binding, 
suggesting that  carbohydrates effected the  interaction  (not 
shown).  Pretreatment  of the lymph node  with mannan,  a 
polymer of mannose,  followed by washing to remove the 
free mannan, and then incubation of the lymph node with 
SA85-1.1  Rg,  blocked the  binding  of SA85-1.1  Rg  (not 
shown). This result indicates that mannan and other carbo- 
hydrates which block ligand binding, recognize a lectin ex- 
pressed by the LN macrophages. The adhesion studies sug- 
gest  that  the  carbohydrates  of SA85-1.1  Rg  also  bind  to 
this LN lectin. 
The  Binding Properties of Soluble SA85-1.1  to LN Macro- 
phages Suggest an Interaction with the Mannose Receptor.  The 
pattern  of carbohydrate inhibition  of SA85-1.1  Rg lectin 
binding was consistent with the lectin's being the MR  (6). 
If SA85-1.1  Rg  carbohydrates  were  binding  to  the  MR, 
then the binding would be calcium dependent and sensitive 
to acidic pH (6).  The binding ofSA85-1.1  Rg to periph- 
eral LN was examined in the presence of varying concen- 
trations  of  Gag12,  and  at  different  H +  concentrations. 
SA85-1.1  Rg binding was detected with GaG12 concentra- 
tions  between  2  mM  and  100  btM  (not  shown).  Weak 
binding was observed with 50  DM Gag12,  and no binding 
with 10 b~M Gag12 (not shown) or 0 IxM CaCl2. Other di- 
valent cations (magnesium and manganese) could not sub- 
stitute for the calcium requirement (not shown). At pH 5.5 
the  SA85-1.1  Rg binding was similar to  that observed at 
neutral pH  (not shown).  No binding was observed at pH 
5.0  and lower,  or above pH 9.0  (not shown).  These data 
are consistent with SA85-1.1  Rg binding to the MR. 
To further examine the possibility that SA85-1.1 Rg was 
binding  to  the  MR,  immunohistochemical  analysis  was 
performed with  SA85-1.1  R.g and  an  anti-MR  antibody. 
Colocalization was noted  between  SA85-1.1  Rg and  the 
anti-MR antibody in peripheral LN (not shown).  This re- 
sult supported the previous data that indicated  that SA85- 
1.1 Rg was binding to the MR. 
1248  T. cruzi Amastigotes Bind the Macrophage Mannose Receptor Figure 5.  The reactivity ofSA85-1.1 Rg with LN is inhibited by mare- 
marian-stage surface glycoproteins. SA85-1.1 Rg binding to LN thin sec- 
tions is shown following pretreatment with 5  p~g/ml spontaneously shed 
surface glycoproteins in the presence ofEDTA (a) or in the absence of 10 
mM EDTA  (b). Staining with  an  irrelevant  human IgG1  antibody  (c). 
￿  660. 
The  Binding of Parasite-synthesized Surface Glycoproteins to 
LN Macrophages Blocks the Binding of SA 85- I. 1 Rg and Is Cal- 
cium-Dependent.  To examine if parasite-synthesized glyco- 
proteins bound to LN macrophages in the same manner as 
SA85-1.1 Rg, initial efforts were made to detect binding of 
spontaneously shed mammalian stage surface glycoproteins, 
which include the SA85-1 glycoproteins (23), with various 
anti-SA85-1  antibodies and mAbs. These studies were dif- 
ficult to interpret because of high background binding of 
antibodies  to  the  LN  thin  sections.  As  an  alternate  ap- 
proach,  spontaneously shed mammalian  stage  surface gly- 
coproteins were used to pretreat LN thin sections, which 
were  subsequently  stained  with  SA85-1.1  Rg.  The  pre- 
treatment  at  a  concentration  of 5  Fg/ml  of protein  was 
found  to  completely block  the  binding  of SA85-1.1  Rg 
(Fig. 5 b). If the pretreatment with spontaneously shed gly- 
coproteins was  done in  the presence of EDTA,  then the 
binding of SA85-1.1  Rg was not inhibited (Fig.  5 a).  Al- 
though the glycosylation of SA85-1.1  Rg by COS cells is 
not likely to  be  identical  to  the  glycosylation of SA85-1 
glycoproteins by T. cruzi, these results suggested that in the 
presence of calcium, the parasite-synthesized glycoproteins 
bound the MR, and inhibited the binding ofSA85-1.1 Rg. 
Amastigotes, but Not Trypomastigotes, Are Recognized by the 
MBP.  Because both the MR and the MBPs bind glyco- 
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Figure 6.  Flow cytornetry of live amastigotes indicating MBP binding. 
(a)  MBP binds to a subset of mammalian-stage parasites. Live tissue cul- 
ture-derived parasites were incubated with 10 I,  zg/ml of MBP or MOPC- 
21, washed and fixed, and the bound MBP was detected with a murine 
anti-MBP mAb, and an anti-routine lg antibody conjugated with FITC. 
Inhibition of MBP binding was demonstrated by the addition of 10 mM 
EDTA.  MOPC-21  mAb was used as  an irrelevant protein  control.  (b) 
The mammalian-stage parasites that bind MBP are twice the relative size 
as the nonbinding parasites. The data in A  are displayed with relative size 
(inferred from forward scatter) on trie X-axis, and MBP binding on the 
Y-axis. Contour intervals represent the relative  number of parasites.  (c) 
MBP binds epimastigotes weakly compared to mammalian stage parasites. 
Live axenic derived epimastigotes were  incubated with  MBP  and anti- 
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 Table 1.  Amastigote Association with J774 Macrophages* 
Condition 
% Association* of 
macrophages with 
i> 1 amastigote  (mean •  SE) 
% Association* ofmacrophages 
with > 1 amastigote 
(mean •  SE) 
MR +, Mannan (1 mg/ml) 
MR +, Glucan (1 mg/ml) 
MR-, No inhibitors 
MR-, mannan (1 mg/ml) 
41  +  5 w  45 --+ 8  w  6 
237 +  611  352 •  3811  1 
42 +  9~  60 _  9 w  9 
136 +  3211  149 +  4311  3 
*J774 macrophages were incubated under serum-free conditions with amastigotes in the presence ofmannan, glucan or media alone. Data are the 
mean •  SE from the indicated number of  independent experiments. 
*% association =  (amastigotes associated with J774 macropbages using different conditions/amastigotes associated with MR+ J774E macropbages us- 
ing media only) ￿  100. 
P <0.05 comparing amastigote association with the indicated macrophages and conditions to MR + macrophages in the absence ofinhibitors, 
IIAssociation was increased rather than decreased. 
conjugates with terminal mannose, fucose, and N-acetyl-D- 
glucosamine, soluble MBP was used to examine T. cruzi for 
the  expression  of these terminal  carbohydrates  (Fig.  6).  In 
Fig, 6 a MBP binds to a subset of mammalian stage parasites 
as  demonstrated  by a  shift  in  the  fluorescent  intensity  of 
greater than 50-fold (Fig.  6  a),  This binding was inhibited 
by the omission of calcium (not shown), or the addition of 
EDTA (Fig. 6 a) indicating that the interaction was calcium 
dependent.  The  mammalian-stage  parasites  that  bound 
MBP  (85.5%)  had  a  relative  size  (inferred  from  forward 
light scatter)  of 38, as compared to a relative size of 15 for 
the nonbinding parasites (14.5%)  (Fig. 6  b). These data sug- 
gest  that  the  spherical  amastigotes  with  greater  forward 
scatter properties bound MBP,  and that the elongated try- 
pomastigotes  did  not.  Fluorescent  microscopy confirmed 
that  only  amastigotes  bound  MBP,  whereas  trypomasti- 
gotes did  not  (not shown).  In addition,  MBP  bound  epi- 
mastigotes  weakly  (a  twofold shift in  fluorescent intensity 
[Fig.  6  c])  compared  to  the  MBP  binding  to  mammalian 
stage  parasites  (Fig.  6  a).  The  data  demonstrated  that  live 
amastigotes  bind  MBP,  and  that  expression  of the  MBP 
ligand is developmentally regulated. 
The incubation of T. cruzi trypomastigotes in LIT media 
for  24  h  results  in  their  conversion  to  amastigotes;  these 
amastigotes are morphologically and antigenically identical 
to  amastigotes  that  develop  intracellularly  (3).  To  further 
examine the developmental regulation of the MBP ligand, 
a mixed population of amastigotes and trypomastigotes was 
converted to amastigotes in LIT media, and the expression 
of the MBP ligand was monitored with flow cytometry. At 
0  b,  both  amastigotes  and  trypomastigotes  were  detected 
(not  shown),  and  only the  amastigotes  bound  MBP  (not 
shown).  After the  24-h incubation  in LIT,  the  cells  were 
>99% amastigotes by phase-contrast microscopy, and 95% 
amastigotes by flow cytometry forward scatter analysis (not 
shown).  The flow cytometry revealed  that  the  amastigote 
population  uniformly bound MBP  (not shown),  and  that 
the  mean  fluorescent  intensity  of MBP  binding increased 
from  10.7  in  the  0-h  amastigotes,  to  19.8  in  the  24-h 
amastigotes (not shown). The data demonstrated that axen- 
ically derived amastigotes express the MBP ligand, and fur- 
ther demonstrated that the MBP ligand is developmentally 
regulated. 
The  MR  Facilitates  the  Adhesion  of Amastigotes  to Macro- 
phages.  The flow cytometry studies demonstrated an inter- 
action  between  amastigotes  and MBP,  and  suggested  that 
amastigotes would also bind to the MR. An interaction be- 
tween  amastigotes  and  the  MR  may facilitate  amastigote 
entry into macrophages; therefore, the adhesion ofamastig- 
otes  to  a  variety of macrophages  was  investigated  (Fig.  7 
and Tables  1-4). 
Amastigote adhesion to the J774E  macrophage cell line 
(MR +)  and  the J774A macrophage  cell line  (MR-)  were 
compared  at  different  multiplicities  of infection  (m.o.i.); 
this  experiment  revealed  that  more  amastigotes  associated 
with the MR + macrophages (Fig.  7, a and b).  Because the 
amount of amastigote association with macrophages varied 
in  independent  experiments,  the  cumulative  data  from 
multiple  experiments  is  presented  as  percent  association 
(Tables  1-4). The cumulative data using the J774 cell lines 
revealed that the MR-  macrophages were associated with 
42% less amastigotes than the MR + macrophages (Table 1). 
Mannan,  a ligand  of the  MR,  inhibited  the  association  of 
amastigotes  with  the  MR +  macrophages,  whereas  glucan 
Figure 7.  The MR contributes to the association of amastigotes with macrophages. Macrophages were incubated with amastigotes at different m.o.i. 
(amastigotes:macrophage) for 2 h, washed, fixed, and then scored for association with/>1  amastigote (left) or >I amastigote (right): (a) and (b) J774 MR + 
and MR- macrophages; (c) and (d) human monocyte-derived macrophages  with mannan (1 mg/ml) and without mannan; (e andf ) mouse thioglycollate 
elicited peritoneal macrophages with mannan (1 mg/ml) and without mannan. The data represent the mean + the standard error of  the mean from three 
determinations. *, P <0.05 comparing (a and b) amastigote association with MR + macrophages to amastigote association with MR- macrophages; and 
(c-f) amastigote association with macrophages in the presence of added carbohydrates to amastigote association with macrophages in the absence of 
added carbohydrates. 
1251  Kahn et al. Table 2.  Amastigote  Association with Human Macrophages* 
Condition 
% Association* of  % Association* of 
macrophages with  macrophages 
i> 1 amastigote  >  1 amastigote 
(mean --- SE)  (mean --- SE) 
Mannan (1 mg/ml) 
Mannan  (0.5  mg/ml) 
Mannan (0.2 mg/ml) 
Glucan (1 mg/ml) 
Glucan (0.5  mg/ml) 
Glucan (0.2 mg/ml) 
Mannose-BSA (0.2 mg/ml) 
Mannose-BSA (0.02 mg/ml) 
Mannose-BSA (0.002 mg/ml) 
Galactose-BSA (0.2 mg/ml) 
Galactose-BSA (0.02 mg/ml) 
46  +  8 w  26 _+  12w  15 
14  +- 8  29 m  14  1 
13  -  7w  21  --- 21  2 
237  +-- 6311  188  +  4311  3 
290  -  13811  455  +-- 18411  2 
200  -  1.2tl  265  --- 6511  2 
29 -  12  w  10 -+ 4w  3 
46  -  19  29  -+  10  1 
63  _+  10  86 +  0  1 
97  +  19  17l  +  4211  l 
94  +  0  86 +  25  I 
* Human monocyte-derived macrophages  were incubated under serum-free conditions with amastigotes  in the presence  of mannan, glucan,  man- 
nose-BSA, galactose-BSA,  or media alone. Data are the mean +  SE from the indicated number of independent experiements. 
*% association  =  (amastigotes associated with human macrophages  using different conditions/amastigotes associated with human macrophages  using 
media only)  ￿  100. 
w  <0.05  comparing amastigote  association with macrophages  in the presence  of various  inhibitors  to amastigote  association with macrophages  in 
the absence of inhibitors. 
II Association was increased rather than decreased. 
did not  (Table  1).  In addition,  mannan  did not inhibit the 
MR-  cell line (Table  1). These initial studies suggested that 
the  MR  facilitates amastigote  adhesion  to  macrophages.  It 
is unclear why glucan augmented the interaction of amasti- 
gotes  with  the  macrophages.  Because  amastigotes  did  ad- 
here  to  MR`-  macrophages,  and  mannan  did  not  com- 
pletely  block  the  association  of  amastigotes  with  MR + 
macrophages,  other  receptors  are  likely to  be  involved in 
adhesion  (Table  1). 
Both human macrophages derived from peripheral blood 
monocytes,  and  thioglycollate-elicited  mouse  peritoneal 
macrophages,  express  high  levels of MR.;  these  cells were 
also used to investigate amastigote invasion (6).  First, man- 
nan  was  shown  to  inhibit  the  association  of amastigotes 
Table 3.  Amastigote Association with Mouse Macrophages* 
% Association* of  % Association* of 
macrophages with  macrophages 
/> 1 amastigote  >  1 amastigote 
Condition  (mean  +- SE)  (mean +  SE)  n 
Mannan  (1 mg/ml)  49 +  9 ~  47  +- 7 w  5 
Mannan (0.5 mg/ml)  67  +  2  100  +__ 0  1 
Mannan (0.2 mg/ml)  52 +  6  47  +  17  1 
Glucan (1 mg/ml)  171  +  2111  192  +  2511  1 
Glucan (0.5 mg/ml)  98 +  17  125  +__ 2511  1 
Glucan (0.2 mg/ml)  108  +  411  117  +-_ 3311  1 
*Thioglycollate elicited mouse peritoneal macrophages  were incubated under serum-free conditions with amastigotes in the presence  of mannan, 
glucan, or media alone. Data are the mean +  SE from the indicated number of independent experiments. 
*% association  =  (amastigotes associated with murine macrophages  using different conditions/amastigotes associated with routine macrophages  using 
media only)  X100. 
,~ P <0.05  comparing amastigote  association with macrophages  in the presence  of various inhibitors  to amastigote  association with macrophages  in 
the absence of inhibitors. 
IIAssociation was increased rather than decreased. 
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% Association* ofmacrophages  % Association* ofmacrophages 
Condition  with t>1 amastigote (mean +  SE)  with >1 amastigote (mean +  SE)  n 
Mannan coated coverslip  63 +  6  60 +  11  2 
* Thioglycollate elicited mouse peritoneal macrophages  were plated on glass coverslips  coated with mannan (50 mg/ml) or BSA (30 mg/ml) for 2 h. 
The slides were then washed and incubated under serum-free conditions with amastigotes in media alone. Data are the mean +  SE from the indi- 
cated number of independent experiments. 
*% association =  (amastigotes  associated with murine macrophages grown on mannan-coated coverslips/amastigotes  associated with murine mac- 
rophages grown on BSA-coated coverslips) ￿ 
with  these  macrophages  at  different  m.o.i.  (Fig.  7,  c-f). 
Cumulative  data  with  the  human  macrophages  demon- 
strated inhibition of amastigote association in the presence 
of mannan or mannose-BSA (Table 2). With routine mac- 
rophages,  the  data  demonstrated  inhibition  of amastigote 
association in the presence of mannan  (Table 3).  In addi- 
tion, the plating ofmurine macrophages on mannan-coated 
coverslips, which  results in the modulation of the MR to 
the basal surface of the macrophages where it is not accessi- 
ble to the amastigotes for adhesion,  reduced amastigote as- 
sociation (Table 4). Again, it is unclear why glucan and ga- 
lactose-BSA  augmented  the  associations  of  amastigotes 
with  human  and  mouse  macrophages  (Tables  2  and  3). 
These  studies  demonstrated  that  the  MR  contributes  to 
amastigote  association  with  macrophages,  and  suggested 
that the MR may facilitate amastigote invasion of a subset 
of macrophages. 
Discussion 
Descriptions of the  T. cruzi life cycle have described amas- 
tigotes as an intracellular replicative form (1). Recent stud- 
ies,  however, have demonstrated that amastigotes circulate 
in the blood stream of infected mammals during the acute 
phase (2),  and that culture-derived amastigotes are resistant 
to complement-mediated lysis (59),  are capable of invading 
macrophages in vitro, and are infective to mice in vivo (3). 
Although  the  role  of extracellular  amastigotes  during  the 
life cycle of the parasite remains unclear, these reports sug- 
gest that amastigotes are not limited to intracellular replica- 
tion;  rather,  amastigotes may contribute to the dissemina- 
tion  of the  parasite  in  the  mammalian  host  and  to  the 
invasion  of mammalian  cells.  The  molecular interactions 
involved  in  amastigote  invasion  of mammalian  cells  are 
poorly defined.  In this  report we have demonstrated  that 
amastigotes interact with two mammalian lectins with sim- 
ilar carbohydrate recognition specificity, the MBP and the 
macrophage MR. We have also demonstrated that the MR 
facilitates amastigote uptake into macrophages. This report 
identifies  the  first  mammalian  lectins  (the  MBP  and  the 
MR)  to  bind  to  T.  cruzi,  and  the  first mammalian lectin 
(the MR) to facilitate T. cruzi invasion of mammalian cells. 
A  definitive  function  for many of the  T.  cruzi surface 
glycoproteins, including the SA85-1 glycoproteins, has been 
difficult to demonstrate.  The  data  in  Fig.  1 demonstrated 
that  the  SA85-1  glycoproteins  are  glycosylated  and  ex- 
pressed as  dimers.  Previous  studies  demonstrated  that  the 
SA85-1  glycoproteins  displayed  extensive  diversity at  the 
amino acid level, and homology to sialidases  (23,  28).  To- 
gether, these data suggested that the SA85-1  glycoproteins 
may function as a family of lectins binding to a variety of 
sialic acid containing oligosaccharides on the surface of host 
cells. To explore this possibility, SA85-1 Rg genes were as- 
sembled,  expressed  in  COS  cells  as  glycosylated  dimers 
(Fig.  2),  and  the  glycoproteins  used  to  screen  normal 
mouse  tissues  for  adhesive  interactions  (Figs.  3  and  4). 
These  experiments  demonstrated  an  interaction  between 
the carbohydrates of SA85-1.1  Rg and the MR; no adhe- 
sive interaction was observed with SA85-1.2 Rg. It is un- 
clear why an  interaction  with  SA85-1.2  Rg was  not  ob- 
served.  Both  SA85-1.1  and  SA85-1.2  encode  potential 
N-linked glycosylation sites  (10 and  11,  respectively). It is 
possible that  SA85-1.2  Rg is glycosylated differently than 
SA85-1.1 Rg. Alternatively, SA85-1.2 Rg may fold in such 
a way that prevents its carbohydrate moieties from binding 
to the MR. 
Previous studies have demonstrated that a known ligand 
of the  MR,  high-mannose  oligosaccharides,  are  a  major 
component of the  T.  cruzi surface glycoproteins, support- 
ing the possibility that these surface glycoproteins, includ- 
ing  the  SA85-1  glycoproteins,  would  be  a  ligand  of the 
MR (7, 60).  Further evidence that the SA85-1  and related 
glycoproteins bind  the  MR  was provided by the  experi- 
ments that demonstrated that the MBP,  a calcium-depen- 
dent lectin with similar carbohydrate binding specificities as 
the  MR,  bound  amastigotes  (Fig.  6).  In addition,  experi- 
ments used MBP-affinity chromatography to  demonstrate 
that  the  SA85-1  glycoproteins  and  related  major  surface 
glycoproteins, expressed by amastigotes bind to MBP  (not 
shown).  An  interaction  between  the  parasite-synthesized 
surface glycoproteins and the MR was further supported by 
the  immunohistochemical  data  that indicate  that parasite- 
synthesized surface glycoproteins, which include the SA85-1 
glycoproteins, bound the MR,  and prevented the binding 
of SA85-1.1  Rg (Fig.  7).  Finally, the flow cytometry data 
indicate  that  the  MBP  and  MR  carbohydrate ligands  are 
expressed in a parasite stage-specific manner (Fig.  6).  Thus 
it appears that both amastigotes and COS  cells  glycosylate 
some  SA85-1  glycoproteins  such  that  they  bind  to  the 
1253  Kahn et al. MBP and the MR. The glycosylation mechanisms enabling 
these different cell types to achieve a related glycosylation 
pattern remain unknown. Taken together, these data indi- 
cate  that  amastigote  surface  glycoproteins,  including  the 
SA85-1  glycoproteins,  are  ligands  of the  MBP  and  the 
MR,  and suggest that the MR may facilitate adhesion of 
amastigotes to macrophages. 
The adhesion assays demonstrated that amastigote associ- 
ation with  macrophages  was  increased by  the  MR.  The 
data  also  indicate  that  other  receptors  contribute  to  the 
amastigote  adhesion  to  macrophages,  as  amastigotes  ad- 
hered to  the  MR-  J774A  macrophages,  and  amastigotes 
adhered to macrophages in the presence of high concentra- 
tions of MR inhibitors. A previous study has demonstrated 
that flbronectin increased amastigote association to resident 
murine  peritoneal  macrophages  and  human  monocytes, 
suggesting  that  flbronectin may  have  contributed  to  the 
binding of amastigotes to macrophages in our assays (61). 
In addition, these experiments were performed in the ab- 
sence of complement; because amastigotes are resistant  to 
the lytic effects of complement (59), it is possible that com- 
plement binding to amastigotes would contribute to their 
opsonization by host cells. 
In  the  adhesion  assays, the  augmented  association  of 
amastigotes with macrophages in the presence of glucan or 
galactose-BSA suggested that these compounds may simul- 
taneously bind to receptors on both the macrophages and 
the amastigotes, which would form a bridge between them, 
and increase their association. The [3-glucan receptor, and 
the  Mac-2  protein  (a  galactose-specific  lectin)  are  mac- 
rophage receptors which may participate in  this  proposed 
interaction (62). 
The  macrophage  MR  recycles  between  the  plasma 
membrane and the lysosomal compartment. Two physio- 
logic functions for this molecule have been proposed: mo- 
lecular scavenging and host defense (6), An example of mo- 
lecular scavenging is the binding of lysosomal hydrolases in 
the extracellular space at sites of inflammation, and the re- 
turn of these enzymes to the macrophage lysosomal com- 
partment (6). In host defense, the MR appears to function 
by binding to terminal mannose residues on the surface of 
microorganisms that results  in  their phagocytosis into the 
lysosomal compartment. Many microorganisms express ter- 
minal mannose residues, which would enable the MR. to 
bind and facilitate their uptake as part of an innate immune 
response (6).  Previous studies have indicated that the MR` 
facilitates the phagocytosis of Canclida species  (63), Saccharo- 
myces  cerevisiae (64),  Aspergillus  fumigatus  (65),  Pseudomonas 
aeruginosa (44), and Pneumocystis carinii (66). In addition, the 
MR facilitates the uptake ofLeishmania  donovani  and patho- 
genic  strains  of Mycobacterium  tuberculosis,  two  organisms 
that proliferate within macrophages (67,  68). Other studies 
have suggested that HIV may gain entry into macrophages 
by binding  to  the  MR  through  carbohydrate residues  of 
gp120 (69). Our data indicate that T. cruzi amastigotes bind 
the MR,  and that the surface glycoproteins, including the 
SA85-1 glycoproteins, are ligands  of this interaction. 
In this report, SA85-1.1 Rg was detected binding to the 
MR expressed by a subset of macrophages in the skin and 
peripheral LN  (Figs.  3  and 4),  while no binding was  de- 
tected  in  cells  in  the  brain,  thymus,  heart,  spleen,  liver, 
small intestine, and kidney (not shown). An explanation for 
this observed binding pattern is that the MR is expressed at 
higher levels by individual macrophages in  skin  and  LN, 
which  permitted  the  immunohistochemical  detection  of 
SA85-1.1  Rg  binding.  Previous  studies  investigating  the 
expression of the MR by individual macrophages have not 
examined the skin or LNs (6). The brightest staining SA85- 
1.1 Rg + rnacrophages were detected in the subcapsular and 
interfollicular sinuses  of the peripheral LN, where afferent 
lymph enters the LN (Fig.  4).  Increased expression of the 
MR in macrophages of the skin and peripheral LN subcap- 
sular  and  interfollicular  sinuses  would  facilitate  the  pro- 
posed MR function in host defense, as microorganisms, in- 
cluding  T.  cruzi,  commonly infect mammals  through the 
skin, and disseminate to peripheral LNs via the lymphatics. 
T.  cruzi  evasion of the  host immune  response is facili- 
tated by its ability to replicate in macrophages. Past studies, 
however,  have  demonstrated  that  rnacrophages  activated 
with IFN-'y are trypanocidal (5). In addition, IFN-2t down- 
regulates the expression of the MR (6). Therefore, our data 
suggest that adherence of T.  cruzi amastigotes mediated by 
the MR may select macrophages that have not been acti- 
vated with IFN-y, and that are permissive for parasite  rep- 
lication. The data also indicate that following infection of 
the skin, a common route of T. cruzi infection, and dissem- 
ination to regional LNs, amastigotes will encounter a subset 
of macrophages that express high levels of the MR and are 
permissive for their replication. 
The experiments demonstrating that amastigotes are re- 
sistant  to  complement (59),  and that amastigotes circulate 
in the blood of infected mammals (2), suggest the possibil- 
ity that MBP,  a  circulating serum protein,  may act as  an 
opsonin and enhance clearance of the parasite.  MBP may 
be considered a member of the collectin family; collectins 
are a  family of molecules that have  a collagen tail,  and a 
carboxyl-terminal  lectin  domain  (70).  The  collagen  tail 
binds to the collectin receptor found on a variety of mam- 
malian  cells  including leukocytes, endothelial cells,  fibro- 
blasts,  and some epithelial  cells;  the lectin domain recog- 
nizes  carbohydrates on  a  wide  variety of microorganisms 
including Leishmania (71), yeasts, certain gram-negative and 
gram-positive bacteria, the hemagglutinin of certain strains 
of influenza virus,  and the HIV gp120  (9).  MBP interac- 
tions with microorganisms may result in opsonization and 
clearance by a variety of cells that express collectin recep- 
tors (9). Alternatively, after binding microorganisms, MBP 
may initiate complement activation via the classic or alter- 
native  pathways  (72,  73).  In  addition,  MBP  may initiate 
complement activation through a novel serine protease, the 
MBP-associated protease (74). 
Previous studies have demonstrated different patterns of 
plant lectin binding to amastigotes and trypomastigotes in- 
dicating  that  differential  glycosylation  occurs  during  the 
parasite life cycle (75). Consistent with these studies,  recent 
reports have indicated that the  trans-sialidase  expressed by 
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participates in trypomastigote invasion of mammalian cells; 
amastigotes  do  not  express  the  trans-sialidase  or  the  sialic 
acid  ligand  (76).  In  addition,  ultrastructural  studies  have 
indicated  that  amastigotes  bind  to  different  regions  of 
mammalian  cells  than  trypomastigotes,  suggesting  that 
amastigote and trypomastigote interactions with host cells are 
different  during  cellular  invasion  (77).  Our  results,  using 
the  human  MBP  as  a  probe,  further  demonstrate  that 
amastigote  glycosidases  generate  oligosaccharide  ligands 
that are distinct  from those found on the surface of trypo- 
mastigotes (Fig. 6). 
The surface glycoproteins and the SA85-1  glycoproteins 
display extensive diversity at the amino acid level, and it has 
been  suggested  that  this  diversity  contributes  to  the  para- 
site's broad host range by enabling a wide variety of inter- 
actions with distinct  cell types.  Previous studies have indi- 
cated that some 85-kD  surface glycoproteins participate in 
adhesion  interactions  with  carbohydrates,  fibronectin,  and 
laminin,  and  that these interactions  contribute  to host  cell 
invasion  (15,  16,  18).  Other  studies  have  indicated  that 
some of these surface glycoproteins function  by disrupting 
the complement system (78,  79). Although  amino acid di- 
versity may play a role in adhesion and entry of amastigotes 
into  cells,  our work suggests that the  patterns  of oligosac- 
charides expressed on these surface glycoproteins may pro- 
vide  a  generic  ligand  for  collectins  like  the  MBP.  One 
could envisage that MBPs,  which are found in all mamma- 
lian sera, may function  to recognize  the  stage-specific gly- 
cosylation  of the  major  surface  glycoproteins  of amastig- 
ores, and thereby enhance  clearance into  a wide variety of 
cells that express collectin receptors. This clearance mecha- 
nism, together with the ability ofamastigotes to resist com- 
plement-mediated lysis (59), may enable the passively mo- 
tile amastigotes to achieve a different cellular tropism than 
the  actively motile  trypomastigotes.  Similarly,  interactions 
with  the  MR  would  enable  amastigotes  to enter non-try- 
panocidal  macrophages.  Although  circulating  MBP  may 
bind  amastigotes  and  block  some  interactions  with  the 
MR,  it  is possible  that  early in  the  infection,  amastigotes 
proliferating  in  the  skin  and  peripheral  LNs,  where  they 
have  not  encountered  MBP,  are  able  to bind  the  MR  of 
macrophages,  whereas  later  in  the  infection,  amastigotes 
circulating  in  the  blood,  are  recognized  by MBP  and  are 
cleared by a variety of cells expressing the  collectin recep- 
tor. These lectin interactions would provide another exam- 
ple  of how  parasites  have  exploited  host  defense  mecha- 
nisms to their advantage. 
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